QT prolongation in the STREAM Stage 1 Trial

G Hughes, H Bern, C-Y Chiang, R L Goodall, A J Nunn, I D Rusen, S K Meredith

Research output: Contribution to journalArticlepeer-review

9 Citations (Scopus)


BACKGROUND: STREAM (Standardized Treatment Regimen of Anti-TB Drugs for Patients with MDR-TB) Stage 1 demonstrated non-inferior efficacy of a shortened regimen (the Short regimen) for rifampicin-resistant TB (RR-TB) compared to the contemporaneous WHO-recommended regimen. This regimen included moxifloxacin and clofazimine, known to cause QT prolongation, and severe prolongation was more common on the Short regimen. Here we investigate risk factors for QT prolongation with the Short regimen.METHODS: Data from patients prescribed the Short regimen (n = 282) were analysed to identify risk factors for severe QT prolongation (QT/QTcF ≥500 ms or ≥60 ms increase in QTcF from baseline).RESULTS: Of the 282 patients on the Short regimen, 94 (33.3%) developed severe QT prolongation: 31 QT/QTcF ≥500 ms; 92 experienced ≥60 ms QTcF increase from baseline. The median time to QT/QTcF ≥500 ms was 20 weeks (IQR 8-28), and the time to ≥60 ms increase from baseline was 18 weeks (IQR 8-28). Prolongation ≥500 ms was most frequent in patients from Mongolia (10/22, 45.5%) compared with 3.5-11.9% at other sites, P < 0.001. Higher baseline QTcF increased risk of prolongation to ≥500 ms (QTcF ≥400 ms: OR 5.99, 95% CI 2.04-17.62).CONCLUSION: One third of patients on the Short regimen developed severe QT prolongation. QT/QTcF ≥500 ms was more common in patients from Mongolia and in those with a higher baseline QTcF, which may have implications for implementation of treatment.

Original languageEnglish
Pages (from-to)334-340
Number of pages7
JournalThe international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease
Issue number4
Publication statusPublished - Apr 1 2022


  • Clofazimine/adverse effects
  • Electrocardiography
  • Heart Rate
  • Humans
  • Long QT Syndrome/chemically induced
  • Moxifloxacin/adverse effects
  • Tuberculosis, Multidrug-Resistant/drug therapy


Dive into the research topics of 'QT prolongation in the STREAM Stage 1 Trial'. Together they form a unique fingerprint.

Cite this